Evidence map›Paper›PMID 40376176›Full record

ArticleChina CDC weekly2025

A Multi-Regional Epidemiological Evaluation on Post-vaccination Serological Testing in Prevention of Vertical Transmission of Hepatitis B Virus - 10 Counties, 5 Provinces, China, 2019-2024.

Lin Tang, Lun Li, Lifang Huang, Jing An, Yang Zhou, Yi Liu, Xiaoxue Liu, Qianqian Liu, Xiaoqi Wang, Siyu Liu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in China CDC weekly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lin TangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Lun LiDepartment of National Immunization Program, Henan Provincial Center for Disease Control and Prevention, Zhengzhou City, Henan Province, China.
Lifang HuangDepartment of National Immunization Program, Fujian Provincial Center for Disease Control and Prevention, Fuzhou City, Fujian Province, China.
Jing AnDepartment of National Immunization Program, Gansu Provincial Center for Disease Control and Prevention, Lanzhou City, Gansu Province, China.
Yang ZhouDepartment of National Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou City, Zhejiang Province, China.
Yi LiuDepartment of National Immunization Program, Sichuan Provincial Center for Disease Control and Prevention, Chengdu City, Sichuan Province, China.
Xiaoxue LiuNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Qianqian LiuNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Xiaoqi WangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Siyu LiuNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Hong YangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Ning WenNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Zundong YinNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Fuzhen WangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

What is already known about this topic?: Post-vaccination serologic testing (PVST) of infants born to hepatitis B virus (HBV) infected mothers is important for evaluating effectiveness of strategies for preventing mother-to-child transmission (MTCT) of HBV. What is added by this report?: PVST was conducted in 43.7% of 7,425 infants born to HBV-infected mothers and showed that 0.8% of infants had breakthrough infections, indicating a very low level of prevention failure; anti-HBs positivity was 97.0% showing vaccine-induced protection; and 2.2% of HBV-exposed infants needed revaccination. Prevention failure was 12.7-fold higher among infants born to HBeAg-positive mothers. What are the implications for public health practice?: MTCT prevention strategy is highly effective. PVST evaluates MTCT prevention strategy and identifies infants needing revaccination; its use should be increased. Findings support WHO's HBV elimination strategy.

Indexed as

HBsAgHepatitis B Virusmother-to-child transmissionPost-vaccination serological testing

Identifiers

PMID40376176
PMCPMC12075494

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.